CA
NZ
UK
AU
IND
US
UnitedHealth Group published third-quarter results on October 13, 2026. Adjusted EPS of USD 4.69 compared with expectations of roughly USD 4.15, while revenue of USD 112.7 billion was 0.4% lower year over year but still above estimates. Management raised its 2026 adjusted EPS outlook …
No company statement dated October 14, 2026 was located to explain the 3.51% gain, which occurred on light trading. The latest company development was the September 28 announcement that IMPAVIDO was available in the United States. Eton said the drug treats visceral, cutaneous and …
No company announcement dated October 14, 2026 was found, making the 3.45% rise more consistent with continued reaction to the August 5 results than with fresh news. The incretin franchise led revenue growth of 48% to USD 22.97 billion. Mounjaro, Lilly’s tirzepatide product for …
With no company release dated October 14 identified, the 3.35% advance followed the October 8 quarterly update rather than a newly announced development. Product trends were mixed but generally stronger: Auryon atherectomy revenue climbed 14.7% to USD 18.9 million, NanoKnife irreversible electroporation revenue gained …
No October 14 corporate announcement was identified, so the share gain appears to have occurred against a backdrop of recent clinical and launch progress. Arrowhead said quarterly U.S. REDEMPLO (plozasiran) prescriptions approximately doubled, more than 400 individual prescribers had written for the medicine, and …
No corporate announcement dated October 14 was located, so the 3.1% increase appears to reflect the earlier settlement and anticipation of an important oncology meeting rather than a new disclosure. Xencor said Phase 1 results for XmAb819 in clear cell renal cell carcinoma had …
There was no company release dated October 14, 2026, and a relative-strength reading near 15 suggests the 3.1% rise may be an oversold bounce rather than a reaction to fresh news. Tonix sells TONMYA, a sublingual cyclobenzaprine product for fibromyalgia, as well as the …
No Corcept announcement dated October 14 was found; the 3.04% advance on thin trading appears to sit against its July results and upcoming regulatory dates. The FDA approved Lifyorli (relacorilant) with nab-paclitaxel for platinum-resistant ovarian cancer in March 2026, while a European decision was …
Medtronic announced on October 14 the final results of its exchange offer for MiniMed Group, which expired on October 9 and was oversubscribed, with 297,521,390 Medtronic ordinary shares validly tendered. Medtronic accepted 55,032,401 shares in exchange for all of its remaining 252,813,348 MiniMed shares, …
AbbVie's board declared on September 10 a quarterly cash dividend of USD 1.73 per share, payable on November 16 to stockholders of record on October 15, and the company has raised its dividend by more than 330% since its inception in 2013. On October …
Please wait processing your request...